Related Experiment Video
Updated: Nov 26, 2025
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Micro-RNA Analysis in Pulmonary Arterial Hypertension: Current Knowledge and Challenges
Cátia A Santos-Ferreira1,2, Mónica T Abreu3,4,2, Carla I Marques3,4,2
1Cardiology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Abstract:
Pulmonary arterial hypertension (PAH) is a rare, chronic disease of the pulmonary vasculature that is associated with poor outcomes. Its pathogenesis is multifactorial and includes micro-RNA (miRNA) deregulation. The understanding of the role of miRNAs in PAH is expanding quickly, and it is increasingly difficult to identify which miRNAs have the highest translational potential. This review summarizes the current knowledge of miRNA expression in PAH, discusses the challenges in miRNA analysis and interpretation, and highlights 4 promising miRNAs in this field (miR-29, miR-124, miR-140, and miR-204).
Insights
This review explores micro-RNA (miRNA) deregulation in pulmonary arterial hypertension (PAH), highlighting four key miRNAs (miR-29, miR-124, miR-140, miR-204) with significant translational potential for treating this rare vascular disease.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Genetics
Background:
- Pulmonary arterial hypertension (PAH) is a severe, chronic vascular disease with limited treatment options.
- Micro-RNAs (miRNAs) play a crucial role in the multifactorial pathogenesis of PAH through gene expression regulation.
- The rapidly evolving field of miRNA research in PAH presents challenges in identifying therapeutically relevant targets.
Purpose of the Study:
- To review current knowledge on miRNA expression profiles in pulmonary arterial hypertension.
- To discuss the analytical and interpretative challenges in studying miRNAs in PAH.
- To identify and highlight specific miRNAs with high translational potential for PAH therapeutics.
Main Methods:
- Comprehensive literature review of studies investigating miRNA expression in PAH.
- Analysis of existing data on miRNA deregulation in pulmonary arterial hypertension.
- Identification of miRNAs consistently implicated in PAH pathogenesis and progression.
Main Results:
- miRNA expression is significantly altered in patients with pulmonary arterial hypertension.
- Specific miRNAs, including miR-29, miR-124, miR-140, and miR-204, show promise due to their roles in PAH.
- Challenges in miRNA detection and functional validation impact translational efforts.
Conclusions:
- miRNA deregulation is a key feature of pulmonary arterial hypertension pathogenesis.
- miR-29, miR-124, miR-140, and miR-204 represent promising therapeutic targets for PAH.
- Further research is needed to overcome analytical hurdles and advance miRNA-based PAH treatments.
